Psoriatic Arthritis Patients have More Heart Disease

Save

A study of 90 consecutive male (50.3±11.1 years) with psoriatic arthritis (PsA) were were compared to 240 age matched controls without known cardiovascular (CV) diseases who underwent angiography for chest pain and/or multiple CV risk factors.

Statins Don't Increase Risk of Colchicine Myopathy

Save

Neuromyopathy is a rare side effect of chronic colchicine use. Statins are more commonly implicated as a cause of drug-induced myopathy.  

Given the frequent occurrence of the metabolic syndrome, simultaneous use of both colchicine and statins is common.

Weight Loss Improves Psoriasis

Save

Jennsen et al previously reported their findings regarding weight reductions ability to improve cutaneous psoriasis at the European Academy of Dermatology and Venereology (EADV) meeting in 2015, Now their results are published in The American Journal of Clinical Nutrition.

The RheumNow Week in Review – 6 January 2017

Save

Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.

Happy New Year!

Pregnancy Outcomes in Psoriatic Arthritis

Save

Disease Activity Pre-pregnancy During Pregnancy Post-pregnancy
Mild 10 6 4
Moderate 2 6 8
Severe 2 2 2

DMARDs Under Study for Secondary Prevention of Cardiovascular Events

Save

Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.

PPI Safety Issues

Save

There are more than 11 million proton pump inhibitor (PPI) prescriptions written each year in the United States. While these agents have dramatically changed the management and outcome of upper gastrointestinal (GI) erosive and inflammatory disorders, their use has not been without safety concerns.

Cautious Optimism for Biosimilars in Rheumatology

Save

CHMP Recommend Baricitinib for Approval in Europe

Save

Eli Lilly and Company announced last friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib for the treatment of adults with moderate to severely active rheumatoid arthritis (R

Risk of GI Perforations on Biologics

Save

Gastrointestinal perforation is a rare but serious complication that RA patients may be at particular risk for.

Osteoporosis 2016 Year in Review - No new drug approvals, and a crisis in care

Save

No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise.

EULAR 2016 Recommendations on Early Arthritis

Save

Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.

Supreme Court Declines Biosimilar Patent Dispute

Save

The U.S. Supreme Court has declined to hear a case over whether companies that make biosimilar drugs must wait six months after federal approval before they bring them to the market.

Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes

Save

Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients. 

CanVasc Recommendations for ANCA-Associated Vasculitis

Save

ANCA associated vasculitis (AAV) has undergone considerable study and advances in the last few years.

Nonsignificant CV Risk with Actemra vs Enbrel

Save

WASHINGTON -- Rheumatoid arthritis is a recognized risk factor for heart attacks and stroke, but a study comparing two leading biologics found only a non-significant increase in relative risk for patients treated with toclizimab (Actemra) vs etanercept (Enbrel), researchers reported here.

Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study

Save

The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.

The RheumNow Week in Review – 2 December 2016

Save

Dr. Cush highlights reports from this week on RheumNow.com.

CURES Act : House Passes Largest Bill Since Obamacare

Save

The 21st Century Cures Act has become one of the most-lobbied health care bills in recent history, with nearly a half billion dollars being spent on both sides - those for and against the bill.

Rheumatologist Compensation and Manpower

Save

You should use this information to not only fend for yourself, but to more accurately guide trainees into a richly rewarding specialty that pays well and has many distinctions to boast of, including high science, hands-on patient interactions and long-term relationships, great hours, lifestyle and family friendly careers. Our field is in desperate need of high quality, problem-solving practitioners.